🇺🇸 LGND — Ligand Pharmaceuticals Incorporated
Salud Compra fuertePrecio actual
313,52 USD
Máx. histórico
322,75
4 días
Split 1603:1000 del 02/11/2022
Caída desde máximo
-2,86%
Rango 52 semanas
175,89 – 326,63
Variación hoy
+2,12%
Cierre anterior
307,02
Rango de hoy
309,46 – 317,76
Volumen hoy
195.564
Peor caída histórica
-93,34%
06/03/2000 → 19/11/2008
Recuperado en 2694 días
Volatilidad anualizada ⓘ
59,76%
- Nombre completo
- Ligand Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGM
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 47
- PER ⓘ
- 33,04 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 350,92 USD (puede no estar actualizado)
- Primera cotización
- 18/11/1992
- Precio actualizado
- hace 10 horas
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Fecha de pago | Importe por participación |
|---|---|
| 03/04/2007 | 9,3575 USD |
| Fecha | Ratio |
|---|---|
| 02/11/2022 | 1603:1000 |
| 19/11/2010 | 1:6 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 02/02/2024 | 73,35 | 74,80 | 73,32 | 74,54 | +0,50% | 2,02% | 68.400 |
| 01/02/2024 | 73,61 | 74,25 | 71,95 | 74,17 | +1,46% | 3,12% | 75.400 |
| 31/01/2024 | 73,79 | 74,48 | 73,06 | 73,10 | -1,10% | 1,92% | 82.900 |
| 30/01/2024 | 74,65 | 74,65 | 73,41 | 73,91 | -1,53% | 1,66% | 72.100 |
| 29/01/2024 | 76,38 | 76,38 | 74,10 | 75,06 | -1,82% | 2,99% | 75.400 |
| 26/01/2024 | 75,55 | 76,66 | 75,21 | 76,45 | +1,54% | 1,92% | 89.400 |
| 25/01/2024 | 74,79 | 76,66 | 73,10 | 75,29 | +1,51% | 4,76% | 99.000 |
| 24/01/2024 | 74,20 | 74,67 | 72,86 | 74,17 | +0,83% | 2,44% | 76.400 |
| 23/01/2024 | 74,16 | 74,19 | 72,39 | 73,56 | +0,23% | 2,43% | 83.400 |
| 22/01/2024 | 72,84 | 74,00 | 72,50 | 73,39 | +1,20% | 2,06% | 117.800 |
| 19/01/2024 | 71,50 | 72,65 | 70,58 | 72,52 | +1,81% | 2,90% | 95.500 |
| 18/01/2024 | 71,26 | 71,77 | 69,98 | 71,23 | +0,52% | 2,51% | 85.300 |
| 17/01/2024 | 69,98 | 71,99 | 67,53 | 70,86 | -0,30% | 6,37% | 106.100 |
| 16/01/2024 | 71,87 | 71,95 | 70,87 | 71,07 | -2,11% | 1,50% | 88.400 |
| 12/01/2024 | 73,20 | 74,34 | 71,75 | 72,60 | +0,57% | 3,54% | 64.000 |
| 11/01/2024 | 72,85 | 72,85 | 70,90 | 72,19 | -1,84% | 2,68% | 134.100 |
| 10/01/2024 | 73,27 | 73,74 | 72,26 | 73,54 | +0,12% | 2,02% | 104.900 |
| 09/01/2024 | 73,30 | 74,99 | 73,00 | 73,45 | -1,21% | 2,71% | 176.300 |
| 08/01/2024 | 73,78 | 75,15 | 71,54 | 74,35 | +4,97% | 4,89% | 161.200 |
| 05/01/2024 | 69,58 | 71,96 | 68,96 | 70,83 | +0,67% | 4,31% | 139.600 |
| 04/01/2024 | 70,34 | 72,03 | 68,80 | 70,36 | +0,46% | 4,59% | 103.900 |
| 03/01/2024 | 71,74 | 72,32 | 69,50 | 70,04 | -3,14% | 3,93% | 76.100 |
| 02/01/2024 | 71,49 | 73,58 | 71,18 | 72,31 | +1,25% | 3,36% | 92.500 |
| 29/12/2023 | 71,88 | 71,89 | 70,94 | 71,42 | -0,58% | 1,32% | 83.300 |
| 28/12/2023 | 72,08 | 72,62 | 71,24 | 71,84 | -0,61% | 1,91% | 52.500 |
| 27/12/2023 | 72,98 | 73,74 | 71,99 | 72,28 | -0,48% | 2,40% | 105.600 |
| 26/12/2023 | 71,50 | 73,50 | 70,75 | 72,63 | +1,57% | 3,85% | 79.300 |
| 22/12/2023 | 71,24 | 72,89 | 71,05 | 71,51 | +0,96% | 2,58% | 102.000 |
| 21/12/2023 | 69,85 | 71,27 | 68,76 | 70,83 | +2,16% | 3,59% | 88.800 |
| 20/12/2023 | 70,60 | 72,19 | 69,27 | 69,33 | -1,28% | 4,14% | 126.800 |